Description: GENinCode Plc, a cardiovascular disease company, focuses on predictive genetics for the prevention of cardiovascular disease. Its predictive technology provides patients and physicians with preventative care and treatment strategies. The companyÂs invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset. It operates business in Europe and Latin America. The company was incorporated in 2018 and is based in Oxford, the United Kingdom.
Home Page: www.genincode.com
GENI Technical Analysis
One St Peters Square
Manchester,
M2 3DE
United Kingdom
Phone:
44 1865 955 847
Officers
| Name | Title |
|---|---|
| Mr. Matthew Heaton Walls | Co-Founder, CEO & Director |
| Mr. Jordi Puig Gilberte | Co-Founder, COO & Director |
| Mr. Paul Andrew Peter Foulger | CFO, Company Secretary & Director |
Exchange: LSE
Country: UK : United Kingdom
Currency: Pence sterling (p)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.3897 |
| Price-to-Sales TTM: | 2.5874 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 42 |